Baricitinib has been given restricted emergency use approval by India's drug regulator for use in combination with remdesivir for the treatment of hospitalised COVID-19 adult patients requiring supplemental oxygen, Cipla said in a filing to stock exchanges.from Industry-Economic Times
Read The Rest:economictimes...
